38.18
+0.68(+1.81%)
Currency In USD
| Previous Close | 37.5 |
| Open | 37.99 |
| Day High | 38.18 |
| Day Low | 37.02 |
| 52-Week High | 39.01 |
| 52-Week Low | 13.15 |
| Volume | 3,013 |
| Average Volume | 9,292 |
| Market Cap | 99.93M |
| PE | -11.57 |
| EPS | -3.3 |
| Moving Average 50 Days | 27.56 |
| Moving Average 200 Days | 20.43 |
| Change | 0.68 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $140.16 as of December 26, 2025 at a share price of $38.18. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $479.65 as of December 26, 2025 at a share price of $38.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
GlobeNewswire Inc.
Oct 09, 2025 12:00 PM GMT
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trialsHIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical com
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonistHIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will